|
Insurance & Litigation
•
|
Tools & Information
•
•
•
|
|
 Back to PRWeb Archives
PRWeb: 02-13-2006
Recent interdictions of Canadian drug packages by U.S. Customs agents are part of a calculated campaign to intimidate patients who order life-saving medications from licensed online Canadian Pharmacies. Interruptions in established medical therapy are putting patients at unnecessary risk. [PRWEB Feb 13, 2006]
SCIREX Corporation, a leader in the delivery of drug development services to the global pharmaceutical and biotechnology industries, this month celebrates the 10th anniversary of its incorporation. [PRWEB Feb 12, 2006]
Over Super Bowl weekend, EQ guaranteed partygoers the ability to have good times longer by providing EQ Effervescent Energy Tablets at evening affairs such as the "Legends" party hosted by NFL star Julius Curry. With nearly 1,000 V.I.P. guests present, empty EQ wrappers adorned the venue's floor and table as guests experimented with EQ in different beverages to keep them energized for all the evening's entertainment. Some guests were overheard saying that the party was better than the game between the Pittsburgh Steelers and the Seattle Seahawks. [PRWEB Feb 10, 2006]
An FDA Advisory Panel voted on February 9 in favor of a 'Black Box' warning on the stimulant medicines. Dr. Kenny Handelman has created a Special Report to help people to understand what this means to the treatment of ADHD. [PRWEB Feb 10, 2006]
Medicationprompt.com announces new release of its popular web-based service to automatically remind people to take their medications through text messages on their cell phones. [PRWEB Feb 10, 2006]
Cardiocore Lab, Inc., a premier provider of centralized cardiac safety monitoring and analysis, announced an unprecedented achievement in electrocardiograph (ECG) data management. The company delivered a clean Thorough QT (TQT) data set?more than 13,000 ECGs?only five days after the study?s final ECG was acquired. With this accomplishment, Cardiocore sets a new standard for cardiac core lab performance. [PRWEB Feb 10, 2006]
Research and Markets (http://www.researchandmarkets.com/reports/c32188) has announced the addition of Cough, Cold and Allergy (Hay Fever) Remedies in Sweden to their offering. [PRWEB Feb 10, 2006]
Research and Markets (researchandmarkets.com/reports/c32307) has announced the addition of Metabolomics: The Next Omics Technology for the Diagnostics Industry to their offering. [PRWEB Feb 10, 2006]
FLAVORx has developed formulations to successfuly flavor the most common acid reflux medications. Beyond just flavoring the commercially available forms, FLAVORx has developed methods to provide safer and more effective liquid solutions to treat reflux symptoms. [PRWEB Feb 9, 2006]
Searching for FDA approved prescription pain and muscle relaxants online? Visit: http://www.Pain-Relief-Medications.info which complies with DEA regulations for doctors approving and pharmacy shipping prescription pain and muscle relaxant medications. Online doctor?s or pharmacists consultations are always available. Pain-Relief-Medications.info is committed to meeting and exceeding all government regulations covering this new form of health care provision. [PRWEB Feb 9, 2006]
The National Center on Sleep Disorders approximate about 70 million Americans suffer from a sleep problems, and HERBALmax (www.herbal-max.com) has formulated a new Chinese herbal product for symptoms of insomnia. [PRWEB Feb 9, 2006]
SCIREX Corporation today announced the appointment of Susan Shelby, PhD to the position of Executive Director, Clinical Trials Management. [PRWEB Feb 9, 2006]
ArtJen is pleased to announce that its new weight loss product FBCx is now available in all Windsor and area Health Smart Drug Stores. This marks the first time that ArtJen?s dietary weight loss supplement has been made available in Canadian pharmacies. [PRWEB Feb 9, 2006]
The attractiveness of the Chinese market is obvious, however intellectual property (IP) violation is also a worrying concern for many. This European Patent Office endorsed workshop will clarify the requirements for effective IP strategy in China. The workshop will be held at the Grand Hyatt Hotel, Shanghai on 30 - 31 March 2006 [PRWEB Feb 9, 2006]
HCPro to distribute proprietary physician intelligence via e-zine for pharmaceutical professionals [PRWEB Feb 9, 2006]
New cap fits sterile water bottles, expanding the line of Baxa accessories that facilitate easy access with Exacta-Med® Oral Dispensers. Designed to ensure dose accuracy while preventing med errors and wrong-route administration of IV drugs, oral dispensers and accessories are recommended by the Institute for Safe Medication Practice (ISMP) for use in oral and enteral fluid drug delivery. [PRWEB Feb 9, 2006]
[PRWEB Feb 9, 2006]
[PRWEB Feb 9, 2006]
4th Annual Generic Drug ForumApril 6-7, 2006 | Washington, DC | There are many issues that Generic Drug manufacturers face in expanding their product offerings and taking them to market. When looking at the marketing and business development side of the generic drug market, there are a lot of challenges that companies are facing. It becomes increasingly difficult for generic drug manufacturers to make decisions on what drug would be the best to move forward into production. It is also important to know what the branded pharmaceutical companies are planning for future product developments, as well as with their current branded therapies, as many companies, when considering the expiry of their blockbusters? patent, will consider re-launching or redeveloping the therapy in order to elongate or continue the brand. Reaching patients and creating access to generic drugs has become one of the largest challenges faced by the industry as people, in general, do not consider them to be ?bioequivalent? to their branded partners. From the production side, there are also a number of important issues to consider. Generic drug manufacturers must insure that the drugs they are producing are exact replicas of the branded drugs in accordance with FDA regulations. This is of increasing importance, as many branded drugs are of an increasingly complex nature, and thus require additional manufacturing quality assurance programs. In some cases, generic drug manufacturers are being told that they need to conduct small to mid-scale clinical trials to prove the efficacy of their products! And, of course, there is increasing FDA surveillance, resulting in large-scale recalls and, to a smaller extent, the liquidation of generic houses. At this conference, we will address these issues through the presentation of case studies and the conducting of panel discussions highlighting the best practices of leading generic drug companies. [PRWEB Feb 9, 2006]
Clinical Research in Emerging CountriesApril 3-4, 2006 | Miami, FL | Aggressive financial targets and intense global competition area creating tremendous pressures on pharmaceutical companies to develop and introduce novel therapies as quickly as possible. But at the same time that speed to market is more important than ever, the growing number of potential new drugs entering clinical development increases competition for the finite numbers of subjects and investigators available in the most popular locations for clinical trials: US, Canada and Western Europe. The emerging shortage on clinical resources can significantly delay the start of a trials for many sponsors. To avoid such delays, many pharmaceuticals companies are using or considering alternatives sites in Latin America, Asia and Central and Eastern Europe to conduct a portion of their clinical trials. [PRWEB Feb 9, 2006]
Brij kicks-off its Southeastern PLAN Affiliate Conference today with participation from over 15 national and regional partners. The PLAN is a unique "partnership of partners" whose Affiliates combine the strengths of their areas of expertise as resellers, systems integrators, service providers, or specialists in specific vertical markets. Since its inception in January 2005, the Partner Leveraged Affiliate Network (PLAN) has grown to include over two dozen Affiliates across the United States. [PRWEB Feb 8, 2006]
Research and Markets (researchandmarkets.com/reports/c32098) has announced the addition of Contrasting European and U.S. Patent Laws: Issues for the Pharmaceutical Industry to their offering. [PRWEB Feb 8, 2006]
Research and Markets (researchandmarkets.com/reports/c32104) has announced the addition of The Impact of Reference Pricing in Europe to their offering. [PRWEB Feb 8, 2006]
Research and Markets (researchandmarkets.com/reports/c32147) has announced the addition of Pharmaceutical Pricing and Reimbursement in Canada to their offering. [PRWEB Feb 8, 2006]
[PRWEB Feb 8, 2006]
[PRWEB Feb 8, 2006]
Research and Markets (researchandmarkets.com/reports/c32170) has announced the addition of Mega Corporation Pipelines: A Postmerger Analysis to their offering. [PRWEB Feb 8, 2006]
Research and Markets (researchandmarkets.com/reports/c32183) has announced the addition of Cough, Cold and Allergy (Hay Fever) Remedies in Japan to their offering. [PRWEB Feb 8, 2006]
Research and Markets (researchandmarkets.com/reports/c32281) has announced the addition of Decision Resources Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2005 to their offering. [PRWEB Feb 8, 2006]
Research and Markets (researchandmarkets.com/reports/c32302) has announced the addition of Key Factors in U.S. Pharmaceutical Pricing to their offering. [PRWEB Feb 8, 2006]
|
|
